

- ⁶⁰ Packer, M.; Carver, J. R.; Rodeheffer, R. J.; Ivanhoe, R. J.; DiBianco, R.; Zeldis, S. M.; Hendrix, G. H.; Bommer, W. J.; Elkayam, U.; Kukin, M. L. und et, a. l.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. *N Engl J Med*, 1991, 325(21), S.1468-1475
- ⁶¹ PEARSON, O. H.; ELIEL, L. P. und et, a. l.: Adrenocorticotrophic hormone- and cortisone-induced regression of lymphoid tumors in man; a preliminary report. *Cancer*, 1949, 2(6), S.943-945
- ⁶² Boesen, E: *Cytotoxic Drugs in the Treatment of Cancer*. Edward Arnold, London, 1969, S.24
- ⁶³ Coley, WB: A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysipelas. *The Post-Graduate*, 1893, 8, S.278-286
- ⁶⁴ Caldwell, A: *Origins of Psychopharmacology: From CPZ to LSD*. Charles C Thomas, Springfield, 1970
- ⁶⁵ Lehmann, HE und Kline, NS: Clinical discoveries with antidepressant drugs. In: Parnham, MJ et al. : *Discoveries in Pharmacology*. Elsevier, New York, 1983, S.209-221
- ⁶⁶ Sulser, F und Mishra, R: The discovery of tricyclic antidepressants and their mode of action. In: Parnham, MJ et al. : *Discoveries in Pharmacology*. Elsevier, New York, 1983, S.233-247
- ⁶⁷ Silverman, W. A.: The schizophrenic career of a "monster drug". *Pediatrics*, 2002, 110(2 Pt 1), S.404-406
- ⁶⁸ GOOD, R. A.; VARCO, R. L.; AUST, J. B. und ZAK, S. J.: Transplantation studies in patients with agammaglobulinemia. *Ann N Y Acad Sci*, 1957, 64(5), S.882-924; discussion, 924
- ⁶⁹ Palca, J.: Insights from broken brains. *Science*, 1990, 248(4957), S.812-814
- ⁷⁰ Wiebers, D. O.; Adams HP, J. r. und Whisnant, J. P.: Animal models of stroke: are they relevant to human disease? *Stroke*, 1990, 21(1), S.1-3
- ⁷¹ Koch, Robert: *British Medical Journal*, 1884, S.454
- ⁷² Altmann, LK: *Who goes first? The story of self-experimentation*. Random House, New York, 1987
- ⁷³ Medicine, Physicians Committee for Responsible: *Ethics in Medical Student Education*. URL: <http://www.pcrm.org/resch/meded/index.html>, Abruf: 27.09.2008
- ⁷⁴ N.V., Crucell: *Crucell's Swiss Affiliate Berna Biotech to Cease All Animal Testing*. 2008
- ⁷⁵ Hartinger, Werner: *Experiments on Animals are scientifically unacceptable / Tierversuche sind wissenschaftlich nicht verwertbar*. Ehlers Verlag, 1993
- ⁷⁶ Hartinger, Werner: *Experiments on Animals are scientifically unacceptable / Tierversuche sind wissenschaftlich nicht verwertbar*. Ehlers Verlag, 1993
- ⁷⁷ (Hg.), *Vereinigung Ärzte gegen Tierversuche*. V.: *Gesundheit & Fortschritt in der Medizin - ohne Tierversuche*. , S.14
- ⁷⁸ Courtine G, Bunge MB, Fawcett JW, et al. Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans? *Nat Med* 2007;13(5):561-566.
- ⁷⁹ Beaud ML, Schmidlin E, Wannier T, et al. Anti-Nogo-A antibody treatment does not prevent cell body shrinkage in the motor cortex in adult monkeys subjected to unilateral cervical cord lesion. *BMC Neurosci* 2008;9:5.
- ⁸⁰ Ärztinnen und Ärzte für Tierschutz in der Medizin. Beispiel 4 fragwürdiger Tierversuche in der Schweiz: Rückenmarksversuche mit Affen an der Uni Fribourg, 2006.
- ⁸¹ Wrigley PJ, Gustin SM, Macey PM, et al. Anatomical changes in human motor cortex and motor pathways following complete thoracic spinal cord injury. *Cereb Cortex* 2009;19(1):224-232.
- ⁸² 180 CHF pro Kind/Jahr laut ECHO (Humanitarian Office of the European Union), 2009.
- ⁸³ "Dokumentation: Das Pharma-Kartell," ZDF. Frontal 21 2008.
- ⁸⁴ "Dokumentation: Das Pharma-Kartell," ZDF. Frontal 21 2008.
- ⁸⁵ "Dokumentation: Das Pharma-Kartell," ZDF. Frontal 21 2008.
- ⁸⁶ A. Sollberger "Tests auf Kosten der Kranken," *Cash* vol. 37, pp. 37-37, 2001.
- ⁸⁷ D. Vonplon "Novartis umwirbt Junge mit Doping-Tabletten," *persoenlich.com - Das Onlineportal der Schweizer Kommunikationswirtschaft* vol. 2010, no. 1.1.2010, 2006.
- ⁸⁸ "Release of innovative training tool for the Integrated Management of Childhood Illness," *express* pp. 1-1, 2008.
- ⁸⁹ "Petition an Novartis," 2007.
- ⁹⁰ "Kein Medikamenten-Patent für Novartis in Indien. *medico international: "Etappensieg für die Medikamentenversorgung in Entwicklungsländern"*, " 2009.
- ⁹¹ "Changing Patterns of Pharmaceutical Innovation," 2002
- ⁹² "A review of new drugs in 2004: Floundering innovation and increased risk-taking," *Prescrire International* vol. 14, no. 76, pp. 68-73, 2005.
- ⁹³ S.G. Morgan, K.L. Bassett, J.M. Wright, R.G. Evans, M.L. Barer, P.A. Caetano and C.D. Black ""Breakthrough" drugs and growth in expenditure on prescription drugs in Canada," *BMJ* vol. 331, no. 7520, pp. 815-816, 2005.
- ⁹⁴ D. Vonplon "Daniel Vasella: «Keine Gratis-Impfstoffe für die Armen»," *Tages Anzeiger* 2009.
- ⁹⁵ T. Schwarz "Einem geschenkten Gaul... Der Coartem-Deal," *Med in Switzerland (Medicus Mundi Schweiz)* vol. 4, 2001.
- ⁹⁶ "Vasella bekommt wieder mehr," *Manager-Magazin* 2009.

⁹⁷ "Diskriminierung - Frauen verlangen 100 Millionen von Novartis," vol. 2009, no. 1.12.2009, .